Аустралија - Енглески - APVMA (Australian Pesticides and Veterinary Medicines Authority)

t.f.h. (australia) pty ltd - mafenide hydrochloride; aminacrine hydrochloride; malachite green - misc. fish tank medication - mafenide hydrochloride amine/amide active 24.2 mg/ml; aminacrine hydrochloride cleanser/sanitiser active 3.3 mg/ml; malachite green dye-green active 0.4 mg/ml - antibiotic & related - fish aquarium | ornamental fish | ornamental fish pond | tropical fish - bacterial disease | general fungal disease | parasitic diseases

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

rising pharma holdings, inc. - mafenide acetate (unii: rq6lp6z0wy) (mafenide - unii:58447s8p4l) - sulfamylon cream is a topical agent indicated for adjunctive therapy of patients with second- and third-degree burns. sulfamylon is contraindicated in patients who are hypersensitive to it. it is not known whether there is cross sensitivity to other sulfonamides.

Канада - Енглески - Health Canada

mylan bertek pharmaceuticals inc. - mafenide (mafenide acetate) - cream - 8.5% - mafenide (mafenide acetate) 8.5% - miscellaneous local anti-infectives

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (united states) - mafenide acetate - cutaneous cream - 85mg/1gram

Бангладеш - Енглески - DGDA (Directorate General of Drug Administration)

navana pharmaceuticals ltd. - mafenide - cream - 8.5 gm/100 gm

Аустралија - Енглески - APVMA (Australian Pesticides and Veterinary Medicines Authority)

aristopet pty ltd - mafenide hydrochloride | aminacrine hydrochloride | malachite green - antibiotic & related - fish aquarium | ornamental fish | ornamental fish pond | tropical fish - bacterial disease | general fungal disease | parasitic diseases

Аустралија - Енглески - APVMA (Australian Pesticides and Veterinary Medicines Authority)

t.f.h. (australia) pty ltd - mafenide hydrochloride | aminacrine | malachite green - dermatological preps. - fish aquarium | ornamental fish | ornamental fish pond | tropical fish - not applicable (vet) | waiting for pest code

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

sanofi-synthelabo ireland ltd - mafenide - cream

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

stratatech corporation - viable and metabolically active allogeneic human niks keratinocytes and human dermal fibroblasts cellularized layered scaffold (unii: dyb2t93463) (viable and metabolically active allogeneic human niks keratinocytes and human dermal fibroblasts cellularized layered scaffold - unii:dyb2t93463) - stratagraft is an allogeneic cellularized scaffold product indicated for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns). do not use in patients with known allergies to murine collagen or products containing ingredients of bovine or porcine origin [see description (11)]. risk summary there are no available data regarding stratagraft use in pregnant women. no animal reproductive and developmental toxicity studies have been conducted with stratagraft to assess whether it can cause fetal harm when administered to a pregnant woman. in the united states general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there is no information available on the presence of stratagraft in human milk, the effect on the breastfed infant, or the effect on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for stratagraft and any potential adverse effects on the breast-fed infant from stratagraft or from the underlying maternal condition. the safety and effectiveness of stratagraft in pediatric patients (< 18 years) have not been established. eight patients aged 65 years and older were enrolled in study 1. although no differences in safety or efficacy were observed between patients aged 65 years and older and younger patients, the number of patients aged 65 years and older was not sufficient to determine whether they responded differently from younger patients.

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

credenhill ltd -